Cognitive changes related to cancer and its treatment have been intensely studied, and neuroimaging has begun to demonstrate brain correlates. In the first prospective longitudinal neuroimaging study of breast cancer (BC) patients we recently reported decreased gray matter density one month after chemotherapy completion, particularly in frontal regions. These findings helped confirm a neural basis for previously reported cognitive symptoms, which most commonly involve executive and memory processes in which the frontal lobes are a critical component of underlying neural circuitry. Here we present data from an independent, larger, more demographically diverse cohort that is more generalizable to the BC population. BC patients treated with (N = 27) and without (N = 28) chemotherapy and matched healthy controls (N = 24) were scanned at baseline (prior to systemic treatment) and one month following chemotherapy completion (or yoked intervals for non-chemotherapy and control groups) and APOE-genotyped. Voxelbased morphometry (VBM) showed decreased frontal gray matter density after chemotherapy, as observed in the prior cohort, which was accompanied by self-reported difficulties in executive functioning. Gray matter and executive symptom changes were not related to APOE e4 status, though a somewhat greater percentage of BC patients who received chemotherapy were e4 allele carriers than patients not treated with chemotherapy or healthy controls. These findings provide confirmatory evidence of frontal morphometric changes that may be a pathophysiological basis for cancer and treatment-related cognitive dysfunction. Further research into individual risk factors for such changes will be critical for development of treatment and prevention strategies.
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Cognitive changes related to breast cancer and its treatment have been an area of increasing study, with numerous reports demonstrating cognitive impairment in patients relative to controls. These changes have been differentially attributed to chemotherapy, radiation, and anti-estrogen treatment (Agrawal et al., 2010; Ahles et al., 2010; Collins et al., 2009; Jim et al., 2009; Quesnel et al., 2009) , and have been reported most prominently in executive functions (e.g., working memory) and processing speed, cognitive processes largely subserved by frontally mediated brain systems (impairment in other cognitive domains has also been noted; for review and meta-analysis see (Anderson-Hanley et al., 2003; Correa and Ahles, 2008; Stewart et al., 2006) ). A higher than expected incidence of impaired cognitive performance has also been found in patients prior to systemic treatment (Ahles et al., 2008; Wagner et al., 2006; Wefel et al., 2004) , suggesting that host factors and/or the cancer disease process itself may play a role. This prior work demonstrates the continued need for further investigation of the effects of cancer treatment and the disease process on cognition in vulnerable individuals (McDonald and Saykin, 2011; Vardy et al., 2008) .
The neural mechanisms underlying these cognitive changes have likewise been the subject of increasing investigation. Several cross-sectional, retrospective structural MRI studies have utilized voxel-based morphometry (VBM) to assess gray matter changes after breast cancer treatment quantitatively, in an automated, unbiased manner (de Ruiter et al., in press; Hakamata et al., 2007; Inagaki et al., 2007; McDonald et al., 2008; Saykin et al., 2003; Yoshikawa et al., 2006) . Those studies comparing gray matter between patients who did and did not receive chemotherapy have demonstrated residual gray matter deficits in the chemotherapy-treated group, even several years after treatment completion (de Ruiter et al., in press; Inagaki et al., 2007; McDonald et al., 2008; Saykin et al., 2003) . We recently reported the first prospective VBM study examining such gray matter changes relative to pre-treatment baseline (McDonald et al., 2010) . We predicted that
